CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Aflibercept

Last Updated: September 16, 2014
Result type: Reports
Project Number: SR0396-000
Product Line: Reimbursement Review

Generic Name: Aflibercept

Brand Name: Eylea

Manufacturer: Bayer Inc.

Indications: Macular edema, diabetic

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: May 7, 2015

Recommendation Type: List with clinical criteria and/or conditions